The tumour suppressor p53, involved in DNA repair, cell cycle arrest and apoptosis, also inhibits blood vessel formation, that is, angiogenesis, a process strongly contributing to tumour development. The p53 gene expresses 12 different proteins (isoforms), including TAp53 (p53 (or p53a), p53b and p53g) and D133p53 isoforms (D133p53a, D133p53b and D133p53g). The D133p53a isoform was shown to modulate p53 transcriptional activity and is overexpressed in various human tumours. However, its role in tumour progression is still unexplored. In the present study, we examined the involvement of D133p53 isoforms in tumoural angiogenesis and tumour growth in the highly angiogenic human glioblastoma U87. Our data show that conditioned media from U87 cells depleted for D133p53 isoforms block endothelial cell migration and tubulogenesis without affecting endothelial cell proliferation in vitro. The D133p53 depletion in U2OS osteosarcoma cells resulted in a similar angiogenesis blockade. Furthermore, using conditioned media from U87 cells ectopically expressing each D133p53 isoform, we determined that D133p53a and D133p53g but not D133p53b, stimulate angiogenesis. Our in vivo data using the chicken chorio-allantoic membrane and mice xenografts establish that angiogenesis and growth of glioblastoma U87 tumours are inhibited upon depletion of D133p53 isoforms. By TaqMan low-density array, we show that alteration of expression ratio of D133p53 and TAp53 isoforms differentially regulates angiogenic gene expression with D133p53 isoforms inducing pro-angiogenic gene expression and repressing anti-angiogenic gene expression.
INTRODUCTION
The well-known tumour suppressor p53 called 'the guardian of the genome' was first described as a single protein. However, we have shown that the p53 gene expresses 12 protein isoforms. 1, 2 Alternative splicing of intron 9 generates p53 isoforms bearing different C-terminal domains (a, b and g; Figure 1a ). The presence of an alternative promoter in intron 4 generates D133p53 isoforms lacking the transactivation domain (TA) and part of the DNAbinding domain. In addition, initiation of translation at alternative AUG codons, codon 40 or codon 160, leads to D40p53 and D160p53 isoforms, respectively. The p53 protein isoforms can be categorized into four subclasses: TAp53, D40p53, D133p53 and D160p53 protein isoforms. Each subclass is composed of the three isoforms a, b and g.
The p53 isoforms are conserved in Drosophila, zebrafish, mouse and human, but little is known about their functions. 2, 3 A gain of expression of D133p53 mRNAs in human breast tumours versus normal breast tissue suggests a protumoural role of these isoforms. 2 Indeed, D113p53, the zebrafish ortholog of human D133p53a, is able to regulate wild-type p53 (WTp53) proapoptotic function. 3 This activity is conserved in human cells, as D133p53a can inhibit p53-mediated apoptosis and G1 cell cycle arrest without inhibiting p53-mediated G2 cell cycle arrest. 4 Furthermore, increased expression of D133p53a is associated with inhibition of replicative senescence in normal human fibroblasts and colon carcinoma. 5 However, no data are available about a direct role of D133p53a in tumour progression.
In addition to its ability to control DNA repair, cell cycle arrest and apoptosis, p53 is involved in inhibition of angiogenesis, a critical mechanism in tumour progression and metastatic dissemination. 6 This process is induced in most solid tumours, whose centres become hypoxic following an increase of the diffusion distance between the nutritive blood vessels and tumour cells. Hypoxia is one of the principal angiogenic stimuli leading to synthesis of angiogenic growth factors and inducing formation of new blood vessels. 7, 8 Such vessels, in addition to their ability to feed tumour cells, provide a way for cells to disseminate and form metastases. p53 inhibits angiogenesis by at least three mechanisms: (1) by regulating expression and activity of the central regulator of hypoxia, the hypoxia-induced transcription factor-1a; (2) by inhibiting production of proangiogenic factors, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2); and (3) by increasing production of anti-angiogenic factors. 6, [9] [10] [11] [12] [13] [14] p53 is able to induce tumour dormancy, and the loss of WTp53 reverses the tumour switch from a dormant non-angiogenic state to an angiogenic invasive phenotype. 15, 16 Clinical data also suggest that p53 has a crucial role in controlling tumour vascularization. However, nothing is known about the role of D133p53 isoforms (a, b and g) in this process.
Among all solid tumours, glioblastoma multiformes are the most angiogenic, by displaying the highest degree of vascular proliferation and endothelial cell hyperplasia. 17 Such intense vascularization has a critical role in the pathological features of glioblastoma multiformes, including peritumoural oedema resulting from the defective blood-brain barrier in the newly formed vasculature. Thus, human glioblastoma U87, expressing WTp53, has been chosen here to address the role of D133p53 isoforms in angiogenesis and tumour progression.
In the present study, we establish by knockdown and ectopic expression experiments that angiogenesis can be regulated by manipulating the expression ratio of D133p53a and p53.
RESULTS

Characterization of p53 isoforms expression in human glioblastoma U87
The expression of p53 isoforms was analysed at the mRNA level by nested reverse transcriptase (RT)-PCR in U87 human glioblastoma cells, which express WTp53 gene. We determined that U87 cells express TAp53 isoforms (p53 (p53a) and p53g) and D133p53 isoforms (D133p53a and D133p53b). The D40p53 isoforms subclass as well as p53b and D133p53g were not detected at the mRNA level (Figure 1b) .
To investigate the role of endogenous p53 isoforms in angiogenesis, U87 cells were transfected with the small interfering RNA (siRNA) siD133p53, which targets specifically the D133p53 isoforms subclass, or with the siRNA siTAp53, which targets specifically the TAp53 isoforms subclass (Figure 1a ). The specificity of the above siRNAs has previously been assessed and validated. 4, 18 Efficiency of siD133p53 and siTAp53 in U87 cells was confirmed by quantitative RT-PCR and western blotting, as compared with the control siRNA (siNON; Figures 1c1, 1c2 , 1d1 and 1d2). As expected, transfection of siTAp53 inhibits p53 mRNA expression, but has no effect on D133p53 mRNA expression. Transfection of siD133p53 in U87 cells represses D133p53 mRNA expression. However, transfection of siD133p53 induces p53 expression at both protein and mRNA levels in U87 cells (Figures 1c2 and 1d2) . Similar results were obtained with another siRNA specific for D133p53 isoforms, siD133p53-2 (Supplementary Figure S1) . 4 Thus, induction of p53 in response to siD133p53 transfection seems to be because of the inhibition of p53 mRNA expression by D133p53 isoforms. Co-transfection of U87 cells with siTAp53 and siD133p53 leads to inhibition of D133p53 expression and prevents induction of p53, maintaining p53 expression at its basal level. Therefore, the expression ratio of endogenous D133p53 and p53 isoforms can be manipulated by transfection of siTAp53 and/or siD133p53.
Tumour-conditioned medium from U87 glioblastoma cells or U2OS osteosarcoma cells transfected with siD133p53 impairs angiogenesis in vitro Anti-angiogenic activities reported for p53 prompted us to look at the effect of D133p53 isoforms in angiogenesis. U87 cells were transfected with siD133p53, siTAp53 or siNON, and the Figure 1 . Regulation of expression of endogenous p53 isoforms in U87 cells. (a) Human p53 gene structure. Alternative splicing of intron 9 generates p53 isoforms bearing different C-terminal domains (a, b and g). TAp53 isoforms include p53 (p53a), p53b and p53g, whereas D133p53 isoforms include D133p53a, D133p53b and D133p53g. 2 The different siRNAs used (siTAp53 and siD133p53) and the regions they target are indicated underneath the p53 gene structure. The different p53 domains are shown: transactivation domains (TA), proline rich domain (PR), DNA binding domain (DNA BD), nuclear localization signal (NLS) and oligomerization domain (OD). (b) Gel electrophoresis (1% agarose) of p53 isoform mRNAs amplified by nested RT-PCR in U87 cells. Total RNA was extracted from U87 cells and nested RT-PCR were performed, as previously described.
2 (c) D133p53 (c1) and p53 mRNAs (c2) relative expression was determined by quantitative RT-PCR following siRNA transfection in U87 cells. Results shown are the average of two independent experiments performed in duplicate. Relative quantification of p53 isoforms was determined by the 2 -DDCt by normalizing to 18S rRNA and control (siNON-transfected U87 cells). 4 Results are presented as percentage compared with control. (d1) D133p53 protein expression was analysed by western blotting after transfection of U87 cells with siRNA (siD133p53 or siNON) and D133p53a expression vector, as indicated. (d2) p53 expression was analysed by western blotting after siRNA transfection (b-tubulin was used as a loading control). The histogram shows densitometry analysis of multiple scanned western blot images to quantify the percentage increase over baseline of p53a (four independent experiments).
D133p53a stimulates angiogenesis H Bernard et al corresponding conditioned medium was added onto human umbilical vein endothelial cells (HUVECs). Migration of HUVECs was then analysed in the wound-healing assay (Figures 2a1 and  2a2 ). The ability of cultured HUVECs to form vessel-like structures (tubulogenesis) on matrigel was also investigated (Figures 2b1 and  2b2 ). Conditioned medium from U87 cells transfected with siD133p53 inhibited HUVEC migration as well as their ability to form vessel-like structures (Figures 2b1 and 2b2) , whereas conditioned medium from U87 cells transfected with siTAp53 had no effect. Interestingly, conditioned medium from U87 cells cotransfected with siTAp53 and siD133p53 had no effect on HUVEC migration and tube formation, as well as proliferation (Figures  2a1-2b2 ). Cell proliferation was also assessed; neither siD133p53 nor siTAp53, nor the double siRNA treatment had any effect on U87 proliferation (Supplementary Figure S2) , and the different conditioned media had no effect on HUVEC proliferation (Figure 2c ). 
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Endothelial cell migration was then studied in a transwell migration assay. In this experiment, adult bovine aortic endothelial cells were seeded in Boyden Chambers and their migration quantified after treatment with conditioned media of siRNAtransfected U87 cells (Supplementary Figure S3) . Here, the knockdown of D133p53 in U87 cells again resulted in a significant decrease of endothelial cell migration, whereas the knockdown of p53 generated a significant increase, suggesting that the absence of increase of HUVEC migration and tubulogenesis following treatment with siTAp53-conditioned media is probably because of experimental conditions. Such an increase would probably have been observed as for the adult bovine aortic endothelial cells, if migration and tube formation would have been quantified at earlier times.
Altogether, these data show that the secretion of angiogenic and/or anti-angiogenic factors by U87 cells into the conditioned medium is regulated by the expression ratio of p53 and D133p53, and suggest that the knockdown of D133p53 in U87 cells impairs the ability of these tumour cells to stimulate angiogenesis.
To determine whether this effect of D133p53 can be generalized to other tumours, HUVEC tubulogenesis was performed using conditioned media of U2OS osteosarcoma cells (WTp53) treated with the different siRNAs. The same data were obtained as for U87 cells, showing that the pro-angiogenic effect of D133p53 is not restricted to U87 glioblastoma (Figure 2d ). D133p53a and D133p53g overexpression stimulates endothelial cell tubulogenesis To determine which D133p53 isoform (a, b or g) is responsible for endothelial cell migration and tubulogenesis, lentivectors expressing each of these isoforms under the control of a tetracyclininducible promoter were used to transduce U87 TetOn cells (Supplementary Figures S4 and S5 ). To measure tubulogenesis, HUVECs were seeded on matrigel as above and incubated in conditioned media produced by doxycycline-treated U87 cells ( Figure 3 ). Data clearly showed that overexpression of D133p53a and D133p53g, but not of D133p53b, are able to stimulate endothelial cell tubulogenesis, suggesting that D133p53a and D133p53g isoforms have a pro-angiogenic activity. As U87 cells express D133p53a and D133p53b, but not D133p53g (Figure 1b) , we concluded that only D133p53a is responsible for the secretion of factors by U87 cells that regulate endothelial cell migration and tubulogenesis of HUVECs.
SiD133p53 inhibits angiogenesis and tumour growth in vivo on the CAM The effect of D133p53a on angiogenesis and tumour growth was addressed in vivo using the experimental glioma assay developed on the chicken CAM, as previously described. 19 This assay recapitulates hallmarks of human glioblastoma multiformes and allows following the first steps of tumoural angiogenesis. The Figure  S7) . Interestingly, tumours resulting from the co-transfection of siTAp53 and siD133p53 looked similar to the ones obtained after transfection of siNON (control). This confirms in vitro data and indicates that angiogenesis can be regulated by altering the expression ratio of p53 and D133p53a.
siD133p53 inhibits angiogenesis and tumour growth in mouse xenografts To study D133p53a involvement in tumour progression, siRNAtransfected glioblastoma U87 cells were subcutaneously implanted in nude mice and followed during 44 days ( Figure 5 and Table 1 ). At day 7 after xenograft, U87 cells transfected with siD133p53 generated significantly smaller tumours compared with U87 cells transfected with siNON ( Figure 5a ). However, tumours generated from U87 cells transfected with siTAp53 or cotransfected with siTAp53 and siD133p53 had similar sizes compared with tumours generated from U87 cells transfected with siNON. The mice were followed until day 44, which clearly showed that tumours generated after siD133p53 treatment of U87 grew significantly more slowly than the control and were drastically smaller than the control at day 35, as well as day 44 (Figure 5b and Table 1 ). However, in contrast to the data obtained at day 7, the size of tumours from U87 cells co-transfected with siD133p53, and siTAp53 was similar to the size of tumours from U87 cells transfected with siD133p53. Angiogenesis was quantified at day 7 by staining of the endothelial cell marker, CD31. Our data showed that tumours from siD133p53-transfected U87 cells were significantly less vascularized at day 7 as compared with tumours from U87 cells transfected with siNON or siTAp53, or co-transfected with siTAp53 and siD133p53 (Figure 5c ).
These results are consistent with the ones obtained in CAM, and confirm that change in expression ratio of p53 and D133p53a regulates angiogenesis and tumour growth in both in vivo models. Hence, an increase of D133p53a compared with p53 would stimulate angiogenesis, whereas an increase of p53 compared with D133p53a would inhibit angiogenesis.
p53 and D133p53a regulate angiogenesis by differentially modulating expression of angiogenesis-related genes To decipher how p53 and D133p53a regulate angiogenesis, expression of 96 angiogenesis-related genes was analysed by TaqMan low-density array in siRNA-transfected U87 cells, as indicated ( Figure 6 ). We used a Taqman human angiogenesis array providing a panel of 96 angiogenesis-related genes (Supplementary Table S1 ). In the control, expression of 14/39 anti-angiogenic genes (35%) and 20/28 pro-angiogenic genes (71%) was detected (Figure 6a) . Results with siD133p53 and siTAp53 were normalized to siNON-transfected U87 cells.
Regarding the anti-angiogenic factors, transfection of siD133p53 significantly induced interleukin 12A (IL12A) and matrix metallopeptidase 2, whereas collagen IV (COL4A2) was significantly repressed ( Figure 6b and Table 2 ). Transfection of siTAp53 induced also the matrix metallopeptidase 2 expression, whereas no change of expression was noted for collagen IV (COL4A1, -A2 or -A3) and XVIII (COL18A1) known as targets of p53. 6 In contrast, IL12A was repressed upon TAp53 isoforms depletion. Interestingly, only IL12A expression was still significantly induced upon cotransfection of U87 cells with siTAp53 and siD133p53. This indicates that anti-angiogenic factors expression is differentially regulated by the expression ratio of D133p53a and p53. Moreover, it suggests that some genes, such as IL12A, are regulated by D133p53a independently of p53.
Regarding the pro-angiogenic factors, angiogenin (ANG), midkine (MDK, neurite growth-promoting factor 2), EGF-like repeats and discoidin I-like domains 3 (EDIL3) and hepatocyte growth factor (HGF) were significantly downregulated upon transfection of siD133p53. In contrast, transfection of siTAp53 had no effect on the level of expression of these genes (Figure 6c) . Interestingly, the level of expression of the classical angiogenic growth factors VEGF, FGF1 and FGF2 was not significantly affected by any of the siRNAs. Moreover, the expression of MDK, EDIL3 and HGF genes remained unchanged in U87 cells co-transfected with siTAp53 and siD133p53, whereas ANG expression was still induced (Figure 6c ). In addition, upon transfection of siD133p53, the angiogenic marker angiopoietin-like 4 is downregulated, a repression that is not observed in U87 cells co-transfected with siTAp53 and siD133p53 isoforms. This indicates that these proangiogenic factors and markers are differentially regulated by the expression ratio of D133p53a and p53 (Figure 6d) . Moreover, it suggests that some genes, such as ANG, are regulated by D133p53a independently of p53.
Altogether, our results indicate that upon transfection of U87 tumour cells with siD133p53, which represses D133p53a expression and induces p53, anti-angiogenic factors are induced, whereas expression of secreted pro-angiogenic factors is repressed.
DISCUSSION
We and others have previously shown abnormal expression of p53 isoforms, including p53b, p53g or D133p53 mRNA expression in human tumours compared with normal corresponding tissue. 20 p53g expression is associated with good prognosis in breast cancer patients expressing mutant p53. 21 Moreover, D133p53a inhibits replicative senescence, p53-mediated apoptosis and G1 cell cycle arrest, without preventing p53-promoted G2 cell cycle arrest by regulating gene expression. [2] [3] [4] [5] Altogether, it suggests that p53 isoforms have a key role in carcinogenesis. However, the role of p53 isoforms in angiogenesis was unknown. The present study reveals that D133p53 is responsible for a strong angiogenesis stimulation that mainly contributes to acceleration of human glioblastoma progression. D133p53 angiogenic effect is due to D133p53a and g, but not the b isoform.
To study the role of p53 isoforms on angiogenesis, we used the glioblastoma U87 model expressing WTp53. Glioblastoma multiformes are the most angiogenic by displaying the highest degree of vascular proliferation and endothelial cell hyperplasia. We have shown that U87 cells express p53 and p53g (TAp53 isoforms), as well as D133p53a and D133p53b (D133p53 isoforms) at the mRNA level. Only p53 protein could be detected at the protein level because of the low affinity of current p53 antibodies and the low expression level of p53 protein isoforms. However, it is important to note that several studies have reported that p53 protein isoforms are biologically active at low expression level. [3] [4] [5] 18, 22 By a knockdown approach using siRNAs specific of TAp53 isoforms or of D133p53 isoforms, we have noticed that siD133p53 concomitantly represses D133p53mRNAs and induces p53 at the mRNA and protein levels in U87 cells, whereas siTAp53 represses p53 expression at the mRNA and protein level without altering expression of D133p53 mRNAs. Interestingly, co-transfection of siD133p53 and siTAp53 represses D133p53 mRNAs expression without inducing p53 expression. As the specificity of siTAp53 and siD133p53 has been previously validated, it suggests that D133p53 isoforms repress p53 expression in U87 cells cultured under standard conditions. We and others have shown that p53 transactivates, in response to stress, the internal p53 promoter giving rise to D133p53 isoforms, thus providing a negative feedback regulation of the p53 response. 3, 4, 18, 23 Altogether, it suggests that p53 and D133p53 isoforms regulate each other's expression in U87 cells. Further experiments will be required to decipher the D133p53-mediated repression of p53 in U87 cells.
By incubating conditioned media from siRNA-transfected U87 cells with primary human or bovine endothelial cells, we have demonstrated that the expression ratio of p53 and D133p53 isoforms regulate endothelial cell migration and tubulogenesis. Furthermore, their ectopic expression has revealed that D133p53a and D133p53g, but not D133p53b, are able to stimulate angiogenesis. As D133p53a and D133p53b, but not D133p53g, are endogenously expressed in U87 cells, we conclude that stimulation of angiogenesis is only because of the endogenous U87 cells transfected with siNON, siTAp53, siD133p53 or siTAp53 þ siD133p53 were xenografted into nude mice. Tumour volumes were quantified from day 7 to day 44 (eight tumours/condition).
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D133p53a in these cells. Using in vitro and in vivo models, we have then established that the p53 and D133p53a regulate angiogenesis by modulating expression of angiogenic-related genes. Hence, an expression ratio of p53 and D133p53a in favour of D133p53a would stimulate angiogenesis whereas an expression ratio of p53 and D133p53a in favour of p53 would inhibit angiogenesis. A previous report showed that D113p53, the zebrafish ortholog of human D133p53a, antagonizes p53-induced apoptosis via Bcl2L activation, and differentially modulates p53 target gene expression. 3 Moreover, D133p53a prevents replicative senescence by inhibiting transactivation of miR-34a by p53. 5 We have recently established that D133p53a inhibits p53-mediated apoptosis and G1 cell cycle arrest, without inhibiting p53-mediated G2 cell cycle arrest. This suggests that D133p53a does not exclusively act by inhibiting p53. This has been confirmed by the fact that p21, Bcl-2 and HDM2 genes are differentially regulated by D133p53a in response to DNA damage. Indeed, D133p53a represses p53 transcriptional activity on p21 promoter, whereas it increases p53-dependent induction of HDM2 expression and induces Bcl-2 expression independently of p53. 4 Therefore, we concluded that D133p53a modulates apoptosis and cell cycle progression in response to stress by regulating gene expression in a p53-dependent and independent manner.
Our present study of angiogenesis-related gene expression by the TaqMan low-density array has figured out that upon siD133p53 transfection, which represses D133p53a and induces p53, several anti-and pro-angiogenic factors are differentially regulated, leading to inhibition of angiogenesis. Reciprocally, upon co-transfection of U87 tumour cells with siD133p53 and siTAp53, which represses (not abolishes) D133p53a expression and maintains p53 expression at basal level, one can expect that anti-angiogenic factors are repressed, whereas expression of secreted pro-angiogenic factors is induced, leading to stimulation of endothelial cell migration and blood vessel formation (tubulogenesis). Our data suggest that D133p53a upregulation affects the angiogenic balance in favour of angiogenesis, and provides an explanation to inhibition of HUVEC tubulogenesis in vitro and tumours angiogenesis in vivo observed in our study. Therefore, angiogenesis through regulation of angiogenesisrelated gene expression could be controlled by modulating the expression ratio of p53 and D133p53a using specific siRNAs.
Moreover, the fact that some pro and anti-angiogenic gene factors (such as IL12A and ANG) are still regulated upon cotransfection of siTAp53 and siD133p53, suggests that such genes are regulated by D133p53a independently of p53. Furthermore, it is important to note that expression of the classical angiogenic VEGF or FGF genes is not significantly altered upon transfection by siD133p53, suggesting a regulation of a distinct signalling pathway involving other angiogenic factors, including ANG, HGF and angiopoietin-like 4.
The present study demonstrates for the first time the direct role of D133p53a isoform in tumour progression. Such a feature may be critical in tumours exhibiting WTp53, which represent about 72% of grade I and 35% of grade II glioblastoma, and for which angiogenesis has been recognized as a key event in their Table 1 ). We considered as relevant repression ( À ) or induction ( þ ) variations superior to two folds. Experiments were repeated twice. Details are presented in Table 2 . 17, 24 Our data may find an important relevance in anti-angiogenic therapeutics of cancer, presently based on angiogenesis inhibitors targeting the VEGF signalling pathway. Such treatments have been proven to be efficacious in patient survival, associated with a chemotherapy. However, although antitumoural effects and survival benefit are often evident, relapse to progressive tumour growth has been recently reported, reflecting multiple mechanisms of adaptation to anti-angiogenic therapies. 25, 26 In this context, D133p53 may have a critical role by stimulating angiogenesis through pathways involving several angiogenic factors distinct from VEGF. Thus, targeting D133p53 may have a strong impact in cancer therapeutics.
MATERIALS AND METHODS
Cells and embryos
HUVECs (Promocell, Heidelberg, Germany) were cultivated in endothelial growth medium-2 containing 2% fetal bovine serum (Cambrex/Lonza, St Beauzire, France). Adult bovine aortic endothelial cells (primary cells) were cultivated as previously described. 28 Human glioblastoma U87-MG (No ATCC: HTB-14, provided by LGCpromochem, Molsheim, France), osteosarcoma U2OS (No ATCC HTB-96) and fertilized chicken eggs (EARL Morizeau, Dangers, France) were handled as described. 19 SiRNA knockdown, cell transfection and western blotting
The siRNAs were purchased from Eurogentec (Liege, Belgium) and SigmaAldrich (Saint-Quentin Fallavier, France). Sequences are provided in Supplementary Table 2 . SiNON served as a negative control. SiTAp53 targets the full transactivation domain (TA) of p53, and SiD133p53 1 and 2 target the 5 0 -untranslated region of D133p53. U87 cells were transfected with siRNAs at 50 nM using InterferIN (Polyplus transfection, New York, NY, USA) or with pD133p53, using FuGENE reagent (Roche, Meylan, France).
Western blots were performed as previously described. 2 Primary antibodies were CM-1 and Sapu 2 for p53 and D133p53, respectively, 2A10 (Abcam, Cambridge, UK) for mdm2, TUB2.1 (Sigma-Aldrich) for b-Tubulin and AC-15 (Sigma-Aldrich) for b-Actin. Horseradish peroxidaseconjugated goat antibodies (Jackson ImmunoResearch, Baltimore, MD, USA), were used as secondary antibodies in immunoblots. Quantitative analysis of the immunoblot data was performed using the ImageJ 1.40g software (Slimware Utilities, D'Iberville, MS, USA).
Lentivector production and U87 cell transduction
The cDNAs coding D133p53a, D133P53b or D133P53g, respectively, were subcloned into the lentivector pTRIP-DU3-TRE-MCS, derived from the selfinactivating lentivector pTRIP-DU3-EF1a-EGFP. 27 The EF1a promoter was replaced by the tetracyclin-inducible pTRE promoter coming from the vector pTRE-tight (Clontech, Issy-Les-Moulineaux, France) and a multiple cloning site was inserted in place of the green fluorescent protein (GFP) gene (Supplementary Figure S4) . The resulting lentivector plasmids were pTRIP-TRE-D133p53a, -D133P53b, and -D133P53g. In parallel, the transactivator TetOn rTTA-advanced from Clontech was subcloned into the lentivector pTRIP-DU3-CMV-MCS in which we had inserted the CMV promoter. U87 cells were transduced with the resulting lentivector pTRIPrTTA-TetOn to generate U87 TetOn cells. Lentivector particles were produced by the Inserm U1037 vector facility (Toulouse, France) from HEK293 cell co-transfection by each plasmid pTRIP with plasmids pLvPack and pLvVSVg (Sigma-Aldrich) coding HIV1 capsid proteins and vasicular stomatitis virus G envelope protein, respectively, as previously described.
Endothelial cell migration, tube formation and proliferation HUVECs migration in the 'wounding assay' was performed during 8 h after treatment with conditioned media from siRNA-transfected U87 or U2OS cells, as described previously. 28 Conditioned media were harvested 72 h after cell transfection and administrated to HUVEC 48 h after starvation.
Adult bovine aortic endothelial cells migration in the transwell migration assay was performed in Boyden Chambers (Millipore, Molsheim, France) according to the manufacturer's instruction. Quantification was performed 6 h after treatment with conditioned media.
To assess the ability of cultured HUVECs to form vessel-like structures in culture (tube formation), Matrigel (BD Biosciences, Le Pont de Claix, France) was added to the wells of an 24-well plate in a volume of 300 ml and allowed to solidify at 37 1C for 30 min. After the Matrigel solidified, HUVECs (5 Â 10 4 cells) were plated in 100 ml of media endothelial growth medium-2 with 0.5% serum and 300 ml of siRNA tumour-cells-transfected supernatant containing 20 ng/ml FGF2 final. Cultures were photographed and the mean number of branch points (s.e.m.) per microscopic field was determined. Studies were performed in triplicate.
Cell proliferation was determined by using the MTT [3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyltetrazolium bromide] assay. HUVECs (2 Â 10 3 per well) were incubated with endothelial basal medium 2 medium with 2% FBS in 96-well plates. HUVECs were serum-starved overnight and incubated in 50 ml of media endothelial growth medium-2 (EBM-2) with 0.5% serum and 150 ml of siRNA tumour cells transfected supernatant containing 3 ng/ml FGF2 final. The medium then was aspirated and MTT was added to each well (0.25 mg/ml). Cells then were incubated for a further 4 h at 37 1C. The medium then was aspirated and the cells were lysed with DMSO and absorbance at 540 nm was measured.
Tumour in CAM and xenografts in mouse Three million siRNA-transfected U87 cells were deposited on CAM as described. 19 A total of 18 digital photos were taken on day 4, using a stereomicroscope (Nikon SMZ800, Champigny s/ Marne, France).
For xenografts, one million cells were injected subcutaneously into nude background (n ¼ 8). Animals were killed 10 days later. Six-week-old nude mice were purchased from Janvier (St Berthevin, France). Mice were injected with 10 6 siRNA-transfected U87 cells subcutaneously into the midback region. The tumour size was measured in three dimensions with calipers twice weekly starting at Day 3. Mice were observed for any change in behaviour, appearance or weight. At the end of the experiment at Day 10, the mice were killed and xenograft specimens were harvested for further analyses.
Tumour volumes were measured according to the international formule V ¼ 1/2 (length Â width 2 ). 29 Length and width were estimated using a stereomicroscope and Adobe photoshop software.
Histology and immunochemistry
Tumours from CAM xenografts were fixed and cryosectioned as decribed. 30 Sections of 10 mm were stained with haematoxylin and eosin. For immunohistology studies, the following primary antibodies were used: Ab-2 (clone V9, NeoMarkers Ab, Montluc¸on, France) for vimentin, Anti Ki-67 (AnaSpec Inc., Fremont, CA, USA) for Ki-67, fluorescein-coupled SNA-1 (AbCys, Paris, France) for SNA-lectin. Cell nuclei were visualized by DAPI (4',6-diamidino-2-phenylindole) dye. Corresponding secondary antibodies were from Molecular Probes (Invitrogen, St Aubin, France). SNA-lectin staining allowed quantification of the capillary network invading the tumour by counting the number of green pixels on each field with Adobe photoshop software. The whole surface of tumours has been counted because of capillary staining heterogeneity (at least five tumours per group).
For mice tumour xenografts, five 5 mM cryosections of tissues were prepared using a Leica cryostat CM3050 (Leica Microsystems, Nanterre, France). Slides were fixed in ice-cold acetone for 2 min, permeabilized in 0.1% Triton X-100 in phosphate buffered saline (PBS), blocked in 5% bovine serum albumin in PBS for 1 h at room temperature and then incubated with 5 mg/ml primary antibodies for 1 h at room temperature. Blood vessels were detected with 5 mg/ml anti-CD31 (BD Pharmingen, Le Pont de Claix, France) antibody. After extensive washing, slides were incubated with 1-2 mg/ml crossabsorbed goat anti-rat DyLight 549 (Tebu-bio, Le Perray en Yvelines, France) secondary antibody for 1 h at room temperature. Slides were counterstained with DAPI (Tebu-bio). Coverslips were mounted with Dako Cytomation fluorescent mounting medium (Dako, Trappes, France). For quantification, number of blood vessels in 5-10 microscopic fields per cryosection (per animal) were quantified and the mean number of vessels ±s.e.m. for the entire treatment group determined.
RNA extraction, nested RT-PCR, real time quantitative RT-PCR and TaqMan low-density array Total RNA was isolated from U87 cells using Nucleospin RNA II kit (Macherey Nagel, Hoerdt, France), assessed and nested RT-PCR was performed as decribed previously. 2 The quantitative PCR was performed on StepOne þ (Applied Biosystems, Villebon s/ Yvette, France) using 10-100 ng of cDNA and Power SYBER Green or TaqMan Universal PCR master mix (Applied Biosystems) for detection of FLp53, D133p53 and 18S.
TaqMan low-density array (Applied Biosystems) was performed following manufacturer's instructions with 50 ng of cDNA. The results were
